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MicroRNAs (miRNA) are small-noncoding RNAs of 21 nucleotides
(nt) that regulate the expression of several genes.1,2 Transcribed
as-primary miRNAs are processed in the nucleus into 70–80 nt,
hairpin-shaped precursors, called pre-miRNAs.1,2 They are then
exported in the cytoplasm and further processed into mature
miRNAs (21 nt), and incorporated in the RNA-induced silencing
complex.1,2
The miR-125b is upregulated in many neoplastic blood
disorders, including acute myeloid leukemia (AML).3–6 Enforced
constitutive overexpression of miR-125b in mice induces myeloid
leukemia.7 It has been indicated that miR-125b in a myeloid
context, might act as an oncomiR able to transform cells by
targeting multiple genes involved in apoptosis, cell cycle and
differentiation (Tili et al.6 and references therein). Relevant to
myeloid leukemia, C/EBPα is frequently mutated in AML, but
surprisingly, none of the observed mutations result in full ablation
of the gene.8,9 This indicates that activity of C/EBPα is required for
Figure 1. miR-125b is upregulated in AML patient samples. (a) qRT-PCR for miR-125 was carried out using bone marrow cells derived from
AML patient samples (n= 10 and healthy donors CD34− cells). Values were normalized to U6 and further to the expression level of three
healthy donors. (b) qRT-PCR for miR-125b was carried out using AML-derived cell lines, values are expressed as fold increase over Jurkat cells.
Values were normalized to U6. (c) qRT-PCR for miR-125 was carried out using PBC cells derived from T-ALL patient samples (n= 7 and healthy
donors CD4+ cells). Values were normalized to U6 and further to the expression level of three healthy donors. (d) qRT-PCR for miR-125b was
carried out using T-ALL-derived cell lines, values are expressed as fold increase over CD4+ healthy donor-derived cells. Values were normalized
to U6. (e) pri-miR-125b-1 and two transcripts were determined by qRT-PCR in the indicated cells. (f) Western blot analysis of Notch1 expression
in whole cell extract in the indicated cell lines. Tubulin is shown as a loading control. (g) DND41 cell line were transfected with either miR-ctr
or mature miR-125b, and mature miR-125b expression was analyzed by qRT-PCR (left). miR-ctr and miR-125b transfected cells were analyzed
by western blot with the indicated antibodies. (h) Left panel, T-ALL- (Jurkat) and AML (HL-60)-derived cell lines were infected with either miR-
ctr/miR-125b or MiRZIP-ctr/MiRZIP125b, and Notch1 mRNA expression was analyzed. Right panel, miR-125b expression was evaluated in the
samples shown in the left panel. All results were expressed as means± s.d., and P-values are indicated.
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AMLs, thus in addition to work as a tumor suppressor C/EBPα
appears to be required for the development of at least some AML
subtypes.8–10 We previously showed that the manifestation of
Hailey–Hailey disease, a rare skin disorder, was in part dependent
on Notch1 downmodulation mediated by miR-125b upregulation.11,12
Notably, although the involvement of Notch signaling as an
oncogene in T-cell acute lymphoblastic leukemia (T-ALL) is well
characterized, Notch signaling acts as a tumor suppressor in
myeloid malignancies. Moreover, although T-ALL cells express
Notch1 receptor, its expression is silenced in AML (Lobry et al.13
and references therein). It has been previously shown that
miR-125b is overexpressed in AML; thus, we investigated whether
Figure 2. miR-125b is a direct target of C/EBPα. (a) Schematic representation of examined putative C/EBPα-binding sites in the promoter
regions of miR-125b. (b) C/EBPα protein expression assessed by western blotting in the indicated cell lines. (c) HEK293T cells were transfected
with miR-125b-luciferase responsive promoter construct, 0.25 μg/well in 24-well dishes, and treated with the indicated amount of C/EBPα; cells
were harvested 24 h after transfection for luciferase assay. All conditions were tested in triplicate samples and s.d. is indicated. (d) Chromatin
derived from HL-60-C/EBPα-positive cells was immunoprecipitated with anti- C/EBPα or IgG antibodies. Recovered DNA was PCR amplified
with primers specific for C/EBPα-binding amplificon. Shown is the fold change in binding affinity of the anti-C/EBPα antibody normalized to
IgG. Immunoprecipitation was performed three times using different chromatin samples, and the occupancy was calculated by using the
ChIP-qPCR Human IGX1A Negative Control Assay (Qiagen, Milano, Italy) as a negative control. As additional control recovered DNA was PCR
amplified with primers specific for Hes-1-binding amplificon in the eIF6 promoter lacking of C/EBPα-binding site.15 (e) miR-125b and C/EBPα
mRNA expression was analyzed at 0, 12, 24 and 48 h post RA treatment of HL-60 cells. (f) miR-125b and C/EBPα mRNA expression in CD34+
versus CD34− human primary cells. (g) miR-125b expression of C/EBPα-silenced HL-60 cells, as assessed by qRT-PCR. (h) A scheme showing
transcriptional regulation and function of miR-125b in AML. miR-125b is induced by both WT and mutant C/EBPα. High expression of
miR-125b leads to differentiation block, proliferation and transformation. In parallel miR-125b decreases Notch1 protein level, which has also
been implicated in suppression of AML cell growth.
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miR-125b overexpression might account for the differential
Notch1 expression between T-ALL and AML. We compared
miR-125b expression pattern in both primary AML and T-ALL
leukemia as well as in AML and T-ALL-derived cell lines (Figures
1a–d). Both the human primary and AML cell lines samples
demonstrated significant upregulation of miR-125b expression.
Conversely, both primary and T-ALL cell lines failed to show
significant enrichment of this miRNA.
In order to investigate whether the deregulation of miR-125b
expression occurs either at the transcriptional or processing
level, primary miR-125b expression levels were analyzed in both
Jurkat and HL-60 cell lines, as well as in primary AML samples
(Figure 1e, Supplementary Figure S1, Supplementary Table 1 and
Supplementary Figure S7). Specifically, quantitative reverse
transcriptase PCR was performed to compare the levels of primary
and mature miRNA. The primary miRNA levels of the miR-125b
were found to parallel mature miR-125b expression in both cell
lines examined (Figures 1b and e). In most primary AMLs, we
found that miR-125b expression was transcriptionally upregulated
(Supplementary Figure S1). Nevertheless, we observe that in some
samples primary miRNAs basal transcription efficiency was
associated with a low abundance of the mature miRNA
(Figure 1a, AMLs 8, 9 and 10). Thus, these observations indicated
that in this cellular context there is generally a high rate of primary
miR-125b transcription, although an altered processing efficiency
might determine the level of mature miRNAs.
We found an inverse correlation of miR-125b expression and
Notch1 protein levels in both T-ALL and AML cell lines, as well as
in primary AML samples (Figures 1b, d and f and Supplementary
Figure S2). We observed higher level of miR-125b expression in
AML when compared with T-ALL samples (Supplementary
Figure S3). Importantly, the Notch1 target genes, Hes-1 and
Deltex1, were significantly higher in T-ALL when compared with
AML (Supplementary Figure S3). Recently, we found that NOTCH1
is a target of miR-125b;12 thus, we analyzed the potential
involvement of miR-125b in regulating the differential expression
of Notch1 between T-ALL and AML cells. We analyzed Notch1
protein expression after overexpression of either miR-125b or
AntagomiR-125b in T-ALL and AML cell lines, respectively.
DND41 cells, but not Jurkat and HL-60 cells, are highly
transfectable. To overcome these limitations, DND41 cells were
analyzed by transient transfection and both Jurkat and HL-60 cells
were transduced by lentiviral infection. We found that deregulated
miR-125b expression impaired Notch1 levels in DND41 (Figure 1g),
and although with a lower effect also in Jurkat and HL-60 cell lines
(Figure 1h). Together, these results suggest that deregulation of
miR-125b expression has a critical role in the differential
expression of Notch1 between T-ALL and AML. However, ME-1
cells devoid of miR-125b expression have undetectable level of
Notch1 expression (Figures 1b and f). Additionally, in the T-ALL
derived cell line, Molt3, miR-125b enforced expression did not
affect Notch1 expression (data not shown); thus, it is likely that
other mechanisms alone or synergistically with the miR-125b are
involved in Notch1 downmodulation in AML14 or alternatively an
unknown mechanism antagonizes the repressive activity of
miR-125b on the 3′-untranslated region of Notch1 in a cell
context-specific manner.
To explore the mechanism regulating miR-125b expression, we
first characterized the miR-125b promoter region using the
Genomatix MatInspector software package (Genomatix Software
GmbH, Munich, Germany), focusing on those transcription
factors that have been shown to have a role in either T-ALL or
AML. A scan of 2 kb of genomic sequence located upstream
of the predicted pre-miR-125b start site identified putative Hes-1,
GATA3 and one C/EBPα consensus binding sites (Figure 2a),
suggesting the involvement of those factors in the regulation of
miR-125b expression. Thus, protein extracts from AML and T-ALL-
derived cell lines were first analyzed for expression of those
factors. Interestingly, C/EBPα expression was correlated with
miR-125b expression in the cell lines examined (Figures 1b–d
and 2b). We next examined the role of these transcription
factors in the regulation of miR-125b expression by generating a
miR-125b promoter construct and testing it in a luciferase reporter
assay. As shown in the Figure 2c, we found the induction of
miR-125b promoter activity by C/EBPα transfection in a dose-
dependent fashion, but neither by HES-1 nor GATA3 (data not
shown), indicating that C/EBPα might be a transcriptional
regulator of miR-125b expression. C/EBPα is a key myeloid
transcription factor, frequently mutated in AML, but none of the
described mutations result in the full loss of its function.10
Recently, it has been shown that C/EBPα-dependent activity has
an important role in AML etiology.10 Next, we investigated
whether C/EBPα directly regulates miR-125b promoter. To test
whether C/EBPα binds directly to the miR-125b promoter, we
performed chromatin immunoprecipitation experiments in both
HL-60 cells and primary AML samples. The chromatin fragments
were immunoprecipitated with an anti-C/EBPα antibody. The DNA
fragments were analyzed with specific primers for the indicated
regions of the miR-125b regulatory region (Figure 2d and
Supplementary Figure S4). We were able to observe an enrich-
ment of DNA from the predicted C/EBPα-binding sites when
compared with the immunoglobulinG control (Figure 2d). Addi-
tionally, we observed an increased recruitment of C/EBPα onto the
miR-125b promoter in AML primary samples highly expressing
miR-125b primary transcript (Supplementary Figures S1 and S4).
The myeloid cell lines provide an important in vitro model
system for studying the cellular and molecular events involved in
the proliferation and differentiation of normal and leukemic cells
of the granulocyte/monocyte/macrophage lineage. Both HL-60
and NB4 pro-myelocytic leukemia cell lines have the potential to
differentiate toward granulocytic lineage by exposure to retinoic
acid. Thus, to explore further the role of C/EBPα in the induction of
miR-125b expression, we compared C/EBPα and miR-125b
expression after retinoic acid treatment (Figure 2e). Treatment
with retinoic acid (1 μM) strongly decreased both C/EBPα
protein and mRNA expression (Figure 2e and Supplementary
Figure S5a), in parallel with induction of granulocytic differentia-
tion (Supplementary Figure S5). Notably, in both cell lines, HL-60
and NB4, the downregulation of C/EBPα expression by retinoic
acid parallels that of miR-125b (Figure 2e and Supplementary
Figure S6). Interestingly a similar parallel expression was observed
in CD34+ and CD34− primary cells (Figure 2f). Finally, small
interfering RNA against C/EBPα in HL-60 abolished the basal level
of miR-125b expression (Figure 2g), further supporting our finding
that miR-125b is a direct target of C/EBPα.
In summary, several studies have made important advances in
elucidating the contribution of both C/EBPα and miR-125b into
the molecular mechanisms of AML development. Our study
implicates the transcription factor C/EBPα as a critical determinant
of miR-125b expression in AML, supporting a model whereby
C/EBPα functions to enhance miR-125b expression to regulate a
group of genes whose deregulation leads to acute myeloid
transformation.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
We thank Professor Stefano Indraccolo for T-ALL samples. This work was supported
by the Italian Association for Cancer Research (AIRC), the Italian Ministry of University
and Research (MIUR), FIRB and PRIN Programs.
Letters to the Editor
2444
Leukemia (2015) 2402 – 2448 © 2015 Macmillan Publishers Limited
AUTHOR CONTRIBUTIONS
CT designed the research, analyzed the data and wrote the paper; IS supervised
the work; PVR, SC, RP and CDB performed experiments; GZ provided AML cell
lines, reagents and analyzed the data; SC and DB commented on the paper. SC
and RF provided AML samples. AA provided T-ALL samples. CT, PVR, SC
assembled the figures.
AUTHOR CONTRIBUTIONS
CT designed the research, analyzed the data and wrote the paper; IS supervised
the work; PVR, SC, RP and CDB performed experiments; GZ provided AML cell
lines, reagents and analyzed the data; SC and DB commented on the paper. SC
and RF provided AML samples. AA provided T-ALL samples. CT, PVR, SC
assembled the figures.
P Vargas Romero1, S Cialfi1, R Palermo2, C De Blasio1, S Checquolo3,
D Bellavia1, S Chiaretti4, R Foà4, A Amadori5, A Gulino1,6,7, G Zardo4,
C Talora1 and I Screpanti1
1Department of Molecular Medicine, Sapienza University of Rome,
Rome, Italy;
2Center for Life Nano Science@Sapienza, Istituto Italiano di
Tecnologia, Rome, Italy;
3Department of Biotechnology and Medical-Surgical Sciences,
Sapienza University, Latina, Italy;
4Department of Cellular Biotechnologies and Hematology, Sapienza
University of Rome, Rome, Italy;
5Department of Surgery, Oncology and Gastroenterology, University
of Padua, Padua, Italy and
6Neuromed Institute, Pozzilli, Italy
E-mail: claudio.talora@uniroma1.it or isabella.screpanti@uniroma1.it
7Dedicated to the cherished memory of Alberto Gulino.
REFERENCES
1 Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:
215–233.
2 Giambra V, Jenkins CR, Wang H, Lam SH, Shevchuk OO, Nemirovsky O et al.
NOTCH1 promotes T cell leukemia-initiating activity by RUNX-mediated
regulation of PKC-theta and reactive oxygen species. Nat Med 2012; 18:
1693–1698.
3 Bousquet M, Harris MH, Zhou B, Lodish HF. MicroRNA miR-125b causes leukemia.
Proc Natl Acad Sci USA 2010; 107: 21558–21563.
4 Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. MiR-125 in normal and
malignant hematopoiesis. Leukemia 2012; 26: 2011–2018.
5 Sun YM, Lin KY, Chen YQ. Diverse functions of miR-125 family in different cell
contexts. J Hematol Oncol 2013; 6: 6.
6 Tili E, Michaille JJ, Croce CM. MicroRNAs play a central role in molecular
dysfunctions linking inflammation with cancer. Immunol Rev 2013; 253:
167–184.
7 So AY, Zhao JL, Baltimore D. The Yin and Yang of microRNAs: leukemia and
immunity. Immunol Rev 2013; 253: 129–145.
8 Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer
2004; 4: 394–400.
9 Ohlsson E, Hasemann MS, Willer A, Lauridsen FK, Rapin N, Jendholm J et al. Initiation
of MLL-rearranged AML is dependent on C/EBPalpha. J Exp Med 2014; 211: 5–13.
10 Roe JS, Vakoc CR. C/EBPalpha: critical at the origin of leukemic transformation.
J Exp Med 2014; 211: 1–4.
11 Cialfi S, Oliviero C, Ceccarelli S, Marchese C, Barbieri L, Biolcati G et al. Complex
multipathways alterations and oxidative stress are associated with Hailey-Hailey
disease. Br J Dermatol 2010; 162: 518–526.
12 Manca S, Magrelli A, Cialfi S, Lefort K, Ambra R, Alimandi M et al. Oxidative stress
activation of miR-125b is part of the molecular switch for Hailey-Hailey disease
manifestation. Exp Dermatol 2011; 20: 932–937.
13 Lobry C, Oh P, Mansour MR, Look AT, Aifantis I. Notch signaling: switching an
oncogene to a tumor suppressor. Blood 2014; 123: 2451–2459.
14 Katzerke C, Madan V, Gerloff D, Brauer-Hartmann D, Hartmann JU, Wurm AA et al.
Transcription factor C/EBPalpha-induced microRNA-30c inactivates Notch1 during
granulopoiesis and is downregulated in acute myeloid leukemia. Blood 2013; 122:
2433–2442.
15 Benelli D, Cialfi S, Pinzaglia M, Talora C, Londei P. The translation factor eIF6 is a
Notch-dependent regulator of cell migration and invasion. PLoS One 2012; 7: e32047.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 4.0 International License. The images or
other third party material in this article are included in the article’s Creative Commons
license, unless indicatedotherwise in the credit line; if thematerial is not included under
the Creative Commons license, users will need to obtain permission from the license
holder to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)
A novel recurrent EP300–ZNF384 gene fusion in B-cell
precursor acute lymphoblastic leukemia
Leukemia (2015) 29, 2445–2448; doi:10.1038/leu.2015.111
In pediatric patients with B-cell precursor acute lymphoblastic
leukemia (BCP-ALL), approximately three-quarters harbor well-
characterized, clinically relevant chromosomal alterations, includ-
ing hyperdiploidy, hypodiploidy, t(12;21) ETV6/RUNX1, t(1;19) E2A/
PBX1, t(9;22) BCR/ABL1 and the rearrangement of MLL at 11q23,
and they can facilitate diagnosis, risk stratification and targeted
therapy.1,2 In the remaining patients, however, major pathogenic
or driver gene abnormalities and their association with the clinical
outcome have yet to be fully clarified. As recent advanced
genomic studies using next-generation sequencing have identi-
fied a number of novel fusion genes and stratified a high-risk
subtype in BCP-ALL,3–5 unknown genetic alterations that consti-
tute characteristic subgroups may still exist in the remaining
patients. We therefore intended to investigate unknown fusion
genes in BCP-ALL by using next-generation sequencing.
As a consequence of whole transcriptome sequencing per-
formed on complementary DNA from 55 selected samples of
pediatric BCP-ALL patients without conventional genetic abnorm-
alities (Supplementary Information), an EP300–ZNF384 fusion gene
was identified in two patients (Cases 1 and 2) as a repeatable and
plausible candidate fusion gene (Figure 1a). The 372-bp fragment
of the EP300–ZNF384 fusion cDNA was amplified by RT-PCR using
a pair of specific primers, and Sanger sequencing of the PCR
products revealed a sequence of the products identical to that
obtained by whole transcriptome sequencing (Supplementary
Figure 1). The presence of EP300–ZNF384 fusion in Case 1 was
further confirmed by FISH using a combination of appropriate
probes for EP300 and ZNF384, respectively (Figure 1b). We
screened a further 346 of pediatric ALL cases by RT-PCR, and
identified 4 additional patients with EP300–ZNF384 fusion (Cases
3–6, Supplementary Figure 1). All six patients were BCP-ALL
without conventional cytogenetic abnormalities. Our RNA samples
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